|Day Low/High||127.13 / 132.44|
|52 Wk Low/High||96.63 / 177.93|
Ocaliva represents the first new treatment option in over 20 years for PBC, an autoimmune liver disease that is the leading reason for liver transplantation in women in Canada
Paratek Pharmaceuticals, Immunomedics and Intercept Pharmaceuticals were among the biotech stock movers in premarket trading Tuesday.
In highlights from this week's trading diary and posts, Kass offers some advice about fundamentals and about what earnings season means.
Intercept says it received approval from the FDA.
Intercept claims FDA approved the OCA study modifications, but like most pharma companies, no proof was offered, just verbal assurances.
The companies inked a $250 million deal on Friday that could be worth up to $2 billion, thanks to milestone payments.
Company to host investor conference call today at 8:30 a.m. ET
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Intercept Pharmaceuticals Inc , where a total of 2,193 contracts have traded so far, representing approximately 219,300 underlying shares. That amounts to about 51.3% of ICPT's average daily trading volume over the past month of 427,725 shares.
Poster presentations explore changes in biochemical markers of disease progression in PBC patients with cirrhosis and renal impairment
But we could see more volatility in the market.
Intercept will collaborate with academic leaders on a new NASH patient registry
Gilead is under enormous pressure from investors to acquire companies or develop new drugs from its pipeline.